Science & Humanity

Defined Research was founded by scientists on a compassionate belief: healthcare supplements should live up to their claims.

It's the only way consumers can trust what's in the bottle – and the only way physicians can trust what they recommend to their patients.

We believe in CBD's promise as a therapy for a variety of human conditions, and we're the only company committed to developing & testing our products to the hightest clinical standards.

Our Approach

  • Research

    Creating a truly effective healthcare product takes time and patience. We spent three years formulating Defined Sleep. Its combination of CBD and eight carefully selected plant-molecules, called terpenes, supports a deep, restorative sleep unlike any other product.

  • Clinical Trials

    All of our products undergo testing in human clinical trials – a standard no other company in our industry has achieved. Our pioneering, double-blind, placebo-controlled, randomized, crossover investigational study tested Defined Sleep's physiological effect in people with insomnia. The results of this exciting study have been submitted for publication in a peer-reviewed scientific journal.

  • Future Therapies

    Beyond insomnia, we believe CBD has the vast potential to provide relief from an array of conditions including, inflammation, pain, autism – and others. As we continue to develop new therapies, our promise is to subject them each to the rigorous research and human clinical studies that shaped the Defined Sleep experience.

Advisory Board

  • Nephi Stella, Ph.D.

    • Professor University of Washington
    • Founder: Stella Therapeutics
    • Discovered second endogenous cannabinoid (2-AG)
    • Thought leader in cannabinoid science (>60 cannabinoid publications)

  • David Housman, Ph.D.

    • Professor Massachusetts Institute of Technology
    • Founder: Genzyme Genetics (Sanofi), Integrated Genetics, Variagenics, Somatix Therapy Corp.
    • Member, National Academy of Sciences and Institute of Medicine

  • Anne Young, M.D./Ph.D.

    • Professor Emeritus Harvard/Massachusetts General Hospital
    • Chair Emeritus, Harvard Neurology
    • Former President, Society for Neuroscience & American Neurological Association
    • Member, Institute of Medicine

  • John Clark, Ph.D.

    • Professor University of Washington
    • Founder: Oculon
    • Former President, Association for Research in Vision and Ophthalmology
    • Thought leader in aging on the eye

Founder and CEO

  • Paul Muchowski, Ph.D.

    • Ph.D. Biological Structure University of Washington
    • Post-doctoral training Max Planck Institute for Biochemistry
    • Professor University of Washington and University of California San Francisco
    • Neuroscience drug discovery (Soteria Therapeutics and Teva Pharmaceuticals)
    • Published >60 highly cited research studies
    • Holds numerous patents
    • Chair Emeritus of the Scientific Advisory Committee for the National Cannabis Industry Association